Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2023
Empagliflozin for the treatment of adults with chronic heart failure with preserved or mildly reduced ejection fraction
1 November 2023 - NICE has published final evidence-based recommendations on the use of empagliflozin (Jardiance) for the treatment of ...
Posted by Michael Wonder on 01 Nov 2023
Cabozantinib maleate for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine
1 November 2023 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) for previously treated ...
Posted by Michael Wonder on 26 Oct 2023
Olipudase alfa for the treatment of patients with acid sphingomyelinase deficiency (Niemann-Pick disease type B and AB)
26 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Oct 2023
First NICE recommended treatment for Parkinson’s set to benefit hundreds
26 October 2023 - Around 900 adults with advanced Parkinson’s are set to benefit from new treatment foslevodopa–foscarbidopa after NICE approved ...
Posted by Michael Wonder on 25 Oct 2023
Baricitinib for the treatment of patients with severe alopecia areata (update)
25 October 2023 - NICE has published final evidence-based recommendations on the use of baricitinib (Olumiant) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Mirikizumab for the treatment of patients with moderate to severe active ulcerative colitis
25 October 2023 - NICE has published final evidence-based recommendations on the use of mirikizumab (Omvoh) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Tirzepatide for the treatment of patients with type 2 diabetes mellitus
25 October 2023 - NICE has published final evidence-based recommendations on the use of tirzepatide (Mounjaro) for the treatment of ...
Posted by Michael Wonder on 25 Oct 2023
Daratumumab in combination with lenalidomide and dexamethasone for untreated patients with multiple myeloma who are ineligible for stem cell transplantation
25 October 2023 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) in combination with lenalidomide ...
Posted by Michael Wonder on 24 Oct 2023
Abiraterone: thousands of men miss out on life-extending prostate cancer drug
24 October 2023 - Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate cancer ...
Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending ...
Posted by Michael Wonder on 19 Oct 2023
Daridorexant hydrochloride for the treatment of patients with long-term insomnia
18 October 2023 - NICE has published final evidence based recommendations on the use of daridorexant hydrochloride (Quviviq) for the ...
Posted by Michael Wonder on 19 Oct 2023
Ruxolitinib phosphate for the treatment of patients with polycythaemia vera
18 October 2023 - NICE has published final evidence based recommendations on the use of ruxolitinib phosphate (Jakavi) for the ...
Posted by Michael Wonder on 19 Oct 2023
Tofacitinib citrate for the treatment of patients with active ankylosing spondylitis
18 October 2023 - NICE has published final evidence-based recommendations on the use of tofacitinib citrate (Xeljanz) for the treatment ...
Posted by Michael Wonder on 18 Oct 2023
Rimegepant sulphate for the treatment of patients with acute migraine
18 October 2023 - NICE has published final evidence based recommendations on the use of rimegepant sulphate (Vydura) for the ...
Posted by Michael Wonder on 17 Oct 2023
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
17 October 2023 - More than 700 people set to benefit from new treatment option for advanced lymphoma. ...